Capmatinib
TABRECTA (capmatinib) is an oral prescription medication from Novartis Pharmaceuticals Corporation, approved to treat adults with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation (MET exon 14 skipping). It comes as film-coated tablets in 150 mg and 200 mg strengths and works by inhibiting certain proteins involved in cancer cell growth. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | TABRECTA (capmatinib) is an oral prescription medication from Novartis Pharmaceuticals Corporation, approved to treat adults with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation (MET exon 14 skipping). It comes as film-coated tablets in 150 mg and 200 mg strengths and works by inhibiting certain proteins involved in cancer cell growth. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Capmatinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Capmatinib — ANDA 213591 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591"
}
]
|
| identifier | ANDA213591 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-manufacturers",
"drug-safety",
"fda",
"pharmaceuticals"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Capmatinib |
